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Introduction
Microparticles (MPs) are sub-micron sized vesicles released by activated or apoptotic cells. 
They are generally defined as 0.1–1 µm membrane particles that expose the anionic 
phospholipid phosphatidylserine (PS) and membrane antigens representative of their cellular 
origin [1]. It is now well recognized that MPs behave as vectors of bioactive molecules, 
playing a role in blood coagulation, inflammation, cell activation and cancer metastasis. In 
clinical practice, circulating MPs originating from blood and vascular cells are elevated in a 
variety of prothrombotic and inflammatory disorders, cardiovascular diseases, autoimmune 
conditions, infectious diseases and cancer [1–3]. As potential disease biomarkers, MP counts 
may provide useful diagnostic or prognostic information or may be used to monitor response 
1See Appendix 1.
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to treatment; however, currently the assessment of their clinical relevance is hampered by 
methodological concerns. Further standardization of protocols for microparticle 
determination are needed to allow multicentre, prospective trials to be conducted, which will 
be critical in establishing the clinical value of these emerging biomarkers and ultimately in 
incorporating MP measurements into routine diagnostic laboratories.
Accordingly, the International Society on Thrombosis and Haemostasis (ISTH) Vascular 
Biology Standardisation Subcommittee (VB SSC) previously organized a first collaborative 
working party aimed at standardizing platelet-derived MP (PMP) measurement by flow 
cytometry [4]. This study demonstrated the utility of fluorescent calibrated beads to improve 
the reproducibility of MP counts; despite significant progress in the analytical phase, a wide 
range of pre-analytical variables (blood handling and centrifugation conditions, use of 
frozen vs. fresh samples, etc.) critically impact on MP measurements and remain a major 
source of variability and potential artifacts in MP analysis, as shown by several studies [5–
11]. Because there is as yet no consensus on which are the major pre-analytical variables 
and which preparation protocol to recommend, the multicenter evaluation of a common pre-
analytical protocol was identified as a priority by the VB SSC. Therefore, the main objective 
of this new workshop was to determine whether it is possible to reduce the inter-laboratory 
variability in MP count and procoagulant activity using a common pre-analytical protocol 
[9] compared with a non-standardized approach.
To this end, 14 participating laboratories prepared platelet-free plasma (PFP) samples from 
well-defined healthy donors (n = 15 per laboratory [range 6–17]) using predetermined 
common pre-analytical conditions (protocol A) on one hand and their own pre-analytical 
conditions (protocol B) on the other hand. In order to reduce the inter-individual variability 
related to gender and potentially age, all healthy volunteers were men aged from 20 to 40 
years of age. Also, stringent conditions were imposed regarding biological data and absence 
of unusual effort on the day before blood collection and/or medication. Detailed information 
regarding protocols was carefully collected in the ‘checking files’ (specimen form provided 
in supporting information).
Protocol A was defined as follows. (i) Blood was collected from fasting subjects in the 
morning (08.00 to 11.00). (ii) Venipuncture of the antecubital vein was performed with a 
≥21-gauge needle following the application of a light tourniquet. The first 2–3 mL of blood 
was discarded. (iii) Citrated plastic tubes (0.109 mol L−1 or 3.2%) with a minimum volume 
of 3.5 mL were used as collection tubes. All the following tubes were not used: citrate-
theophylline-adenosine-dipyridamole (CTAD), ethylenediamine tetraaceticacid (EDTA), 
heparin, acid-citrate-dextrose (ACD) tubes and glass tubes. Anticoagulant was mixed with 
blood by gentle inversion. (iv) When possible, samples were drawn directly in the 
laboratory. If tube transportation was needed, this was carried out carefully to avoid 
unnecessary agitation. For this purpose, a box maintaining blood tubes in a steady vertical 
position was used. Samples were kept at room temperature (20–24 °C) and the delay before 
the first centrifugation was < 2 h. (v) Samples were centrifuged at 2500 ×g for 15 min at 
room temperature avoiding application of the centrifuge brake. Plasma was collected in a 
plastic tube with a 1000-µL pipette, leaving 1 cm of plasma above the buffy layer and taking 
care not to disturb it. The plasma was then centrifuged a second time at 2500 ×g for 15 min 
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at room temperature. PFP was collected into a new plastic tube using a 200-µL pipette, and 
leaving approximately 100 µL at the bottom of the plastic tube. (vi) Homogenized PFP was 
snap-frozen in liquid nitrogen and stored at −80 °C. Collected PFP from both protocols was 
sent in adequate cardboard cryoboxes to the core laboratory in dry ice. This was then 
analyzed using flow cytometry (Gallios; Beckman-Coulter, Villepinte, France) to enumerate 
MP and MP-dependent functional assays to measure their procoagulant activity: thrombin 
generation was measured using the Calibrated Automated Thrombogram® (CAT) and 
phospholipid-dependent coagulation time was measured using the STA®-Procoag-PPL 
assay, both from Diagnostica Stago (Asnières, France). Details regarding materials and 
methods can be found in the Supporting Information.
Among 14 participating laboratories, 11 complied with protocol A’s instructions and were 
included in the analysis. As shown in Fig. 1(A), median PMP counts determined in PFP 
prepared from healthy individuals varied from 180 (7A) to 1400 (2A) PMP per µL, with an 
inter-individual variability ranging from 37% (7A) to 130% (4A). As a whole, PMP counts 
were higher with the non-standardized protocols (Protocol B, Fig. 1B), 420 (4B) to 2100 
(3B) PMP per µL, and showed higher inter-individual variability (62% [6B] to 170% [9B]). 
Interestingly, as seen in Fig. 1, in most laboratories (9/11) this variability was reduced by 
using a standardized protocol rather than the in-house method. Thus, MP counts determined 
in healthy donors were lower and less variable using a common pre-analytical protocol (A). 
This tendency was confirmed by the thrombin generation velocity (Fig. S1) and the 
phospholipid-dependent coagulation time (Fig. S2), with (respectively) a higher thrombin 
generation and a shorter clotting time for protocol B. It varied from a median velocity range 
of 2 (1A) to 10 (2A) nmol L−1min−1 and a median clotting time range of 70 (2A) to 95 (8A) 
seconds for protocol A, as compared with median velocity range of 1 (1B) to 12 (5B) nmol 
L−1 min−1 and median clotting time range of 65 (3B) to 88 (11B) seconds for protocol B. 
However, it cannot be concluded from higher MP counts and thrombin generation and 
shorter clotting time for protocol B, that protocol A is better.
The inter-laboratory reproducibility for MP counts and procoagulant assays was compared 
between protocols. As illustrated in Fig. 1(C), the mean coefficient of variation of the PMP 
counts decreased in protocol A as compared with protocol B (66% [range 64.8–80.3] vs. 
80% [79.6–104.3] respectively), clearly demonstrating the improved reproducibility using 
protocol A. However, the study failed to demonstrate the superiority of protocol A over 
protocol B based on MP-dependent procoagulant assays.
These data illustrate that, despite a significant reduction of the inter-laboratory variability of 
FCM-based PMP counts when using a common sampling protocol, this is still unacceptably 
high for clinical use. Along this line, we noticed critical differences between the requested 
specifications of the common protocol (protocol A) and what was actually applied in three 
laboratories, leading to significant differences in MP counts and procoagulant activities and, 
thus, rejection of these samples from protocol A analysis. Interestingly, and as illustrated in 
Fig. S3, careful re-analysis of these specific cases provided useful information on major pre-
analytical parameters impacting MP analysis, such as the volume of the collection tube (1.8 
or 2.4 mL vs. 3.5 mL) and the amount of plasma left above the buffy layer (5 mm vs. 10 
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mm). As a comparison, incidental thawing of PFP samples during transportation to the core 
laboratory showed a lower influence than the volume of the collection tube.
Furthermore, as could be seen from the checking files, nine laboratories had a different 
centrifugation protocol in protocol B as compared with A. As illustrated in Fig. S4, 
centrifugation force inversely correlates with PMP counts. This result confirms data in the 
literature that identify centrifugation as the main factor affecting MP analysis [8,12–14]. 
Other variables have been shown to have a significant impact on MP pre-analytics, such as 
the time before the first centrifugation and the agitation of the tube transportation [8]; 
however, both these variables have been well controlled during this study. Other parameters 
have not been taken into account, such as the type of the collection and storage plastic tubes 
[15] or the operator experience, and may partly explain the remaining variability.
In conclusion, this workshop showed the ability of a common pre-analytical protocol to 
reduce the inter-laboratory variability of flow cytometric enumeration of PMPs in healthy 
individuals. However, significant variability does remain in some cases even when a 
common protocol is correctly applied, suggesting that other, as yet unidentified, parameters 
could be important in the setting of multicenter studies. Moreover, besides PMPs, which are 
the most sensitive to pre-analytical variables, the benefit of a common standardized pre-
analytical protocol has yet to be evaluated in other MP sub-populations, such as 
erythrocyte-, leukocyte- and endothelial-derived MPs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Impact of the pre-analytical protocol on the inter-individual and inter-laboratory variability 
of MP measurements (A & B). Impact of pre-analytics on inter-individual variability of 
PMP counts by FCM. PMP counts by FCM in normal plasma samples prepared by different 
laboratories using a common pre-analytical protocol (protocol A, upper graph) or their in 
house pre-analytical approach (protocol B, lower graph). Median (dashed line) and 25–75% 
interquartile range (dotted lines) of PMP using protocol A. For example, 1A means 
laboratory number 1, protocol A. ‘All’ accounts for the combination of data from all the 
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laboratories. (C). Impact of pre-analytics standardization on interlaboratory variability of 
PMP counts and procoagulant activities. To determine if the inter-laboratory variability was 
different between protocols for each analyzed parameter, the coefficient of variation was 
calculated for each laboratory. Then a mean coefficient of variation was derived by 
averaging all coefficients related on a parameter. Differences between protocols were 
evaluated used the Bootstrap method and expressed by determination of the confidence 
intervals. The normal approximations method has been used for computing 95% confidence 
intervals. CV, coefficient of variation; CI, confidence interval determined by the Boopstrap 
method (vertical bars).
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